INTRODUCTION {#s1}
============

Glucocorticoids (GCs) are key drugs for the treatment of pediatric acute lymphoblastic leukemia (ALL) \[[@ref1],[@ref2]\]. Their antileukemic effects occur through the induction of apoptosis and/or cell cycle arrest \[[@ref3]\]. However, they give rise to severe side effects, which also show individual variation. Therefore, in this study we focused on individual genetic differences that may lead to increased sensitivity to GCs and their side effects.

GC downstream effects are mediated through the process of binding to an intracytoplasmic glucocorticoid receptor (GR). This receptor gene (*NR3C1*) is located on the long arm of the fifth chromosome (5q31.3). A number of GR polymorphisms have been detected in recent years \[[@ref4],[@ref5]\]. The 1220A/G transition that results in the substitution of asparagine to serine at codon 363 (N363S polymorphism) and the substitution of cytosine (C) to guanine (G) at intron 2 (BclI polymorphism) are related to high sensitivity to GCs \[[@ref6]\]. The C allele is the most frequently occurring and thus can be considered the wild-type allele \[[@ref7]\]. These polymorphisms cause personal variability in the sensitivity and responses to GCs \[[@ref8]\]. In a study by Huizenga et al. \[[@ref5]\], the carriers of the N363S polymorphism had lower cortisol levels after low-dose dexamethasone (0.25 mg) suppression tests. Cuzzoni et al. \[[@ref6]\] showed that the BclI polymorphism caused increased sensitivity to methylprednisolone in human lymphocytes in vitro. Lin et al. \[[@ref9]\] found that the frequency of N363S allele carriers in subjects with coronary artery disease was particularly high. Di Blasio et al. \[[@ref10]\] found that among obese patients, heterozygous N363S carriers had significantly higher body mass index (BMI) when compared to wild-type homozygotes. The BclI polymorphism also plays an important role in certain psychiatric diseases \[[@ref11],[@ref12],[@ref13]\]. The mechanism of GC sensitivity is still incompletely understood but the hypothesis that the BclI polymorphism changes GR dimerization and interactions between transcription factors is suggested \[[@ref14]\].

There is variability in the treatment responses and side effects in patients with ALL \[[@ref15],[@ref16]\], including GC treatment. While there have been a number of investigations of the GC response and GC receptor mutations and polymorphisms \[[@ref3],[@ref17],[@ref18],[@ref19],[@ref20],[@ref21]\], there are a limited number of studies about the side effects of GCs in relation to GC receptor polymorphisms \[[@ref22],[@ref23],[@ref24],[@ref25],[@ref26]\]. We hypothesized that the N363S and BclI polymorphisms could be important in the variability of side effects of GCs among patients with ALL. We think that this information will be important for improving personal treatment modalities in the future.

MATERIALS AND METHODS {#s2}
=====================

Study Population {#s2a}
----------------

The necessary sample size was calculated to be at least 40 individuals in each group, with 80% power and 0.05 type I error while anticipating a deviation of ±20% in the control group (R 3.0.1. open source program), based on the literature data \[[@ref20]\]. Accordingly, a total of 49 patients (age: 1.4-17 years; 31 males, 18 females), 14 and 35 of whom were treated with the St Jude TXIII and Berlin-Frankfurt-Münster (BFM)-TR ALL 2000 protocols (the latter is modified from BFM 95) respectively between 2000 and 2012, were included in the study. Each patient enrolled in this study received GCs during the induction and reinduction phases. The patients received steroids as prednisolone at a daily dosage of 40 mg/m^2^ between day 1 and day 29 during the induction and reinduction phases in the St Jude TXIII protocol \[[@ref2]\]. The types of steroids administered during the BFM-TR ALL 2000 protocol were prednisolone at 60 mg/m^2^/day for 31 days in high-risk and 36 days in standard-risk and intermediate-risk patients during induction (protocol I/phase I) and dexamethasone at 10 mg/m^2^/day during protocol II/phase I (reinduction). Forty-six patients aged 1.2-17.5 years with immune thrombocytopenia, nutritional anemia, or acute infections were included in the control group.

Analysis of Glucocorticoid-Induced Side Effects {#s2b}
-----------------------------------------------

We collected clinical and laboratory data retrospectively from patient files and classified potential side effects of GCs according to the National Cancer Institute's Common Terminology Criteria for Adverse Events, version 4.0 (CTCAE v.4) \[[@ref27]\], which were defined as follows:

**Metabolic and Nutritional Disorders:** Hyperglycemia (fasting glucose value \>100 mg/dL), hypertriglyceridemia (blood triglyceride value \>150 mg/dL), obesity (BMI \>25).

**Endocrine Disorders:** Cushingoid changes (buffalo hump obesity, striations, adiposity, hypertension, diabetes, and osteoporosis).

**Gastrointestinal and Hepatic Disorders:** Dyspepsia (an uncomfortable and often painful feeling in the stomach, burning stomach, bloating, heartburn, nausea, and vomiting), oral mucositis, gastric hemorrhage, and elevation in alanine aminotransferase, aspartate transaminase, and blood bilirubin levels.

**Musculoskeletal and Connective Tissue Disorders:** Arthralgia, arthritis, generalized muscle weakness, myalgia, avascular necrosis, osteoporosis. Hip joint magnetic resonance imaging (MRI) was performed for detection of avascular necrosis if the patient had hip pain during or at the end of the induction and reinduction phases. Bone mineral densitometry (BMD) for osteoporosis was performed at the time of diagnosis and at the end of the induction and reinduction phases. At the end of induction 32 patients and at the end of reinduction 34 patients were investigated for BMD. Z-scores (corrected for age) between -1 and -2.5 and Z-scores below -2.5 were considered "osteopenia" and "osteoporosis," respectively.

**Psychiatric Disorders:** Depression symptoms (melancholic feelings of grief or unhappiness, change in sleep patterns, pessimistic thoughts, thoughts of death).

**Nervous System Disorders:** Leukoencephalopathy.

**Eye Disorders:** Blurred vision, cataract, glaucoma.

**Cardiac Disorders:** Sinus bradycardia, sinus tachycardia.

**Vascular Disorders:** Hypertension, thrombosis (superficial and deep vein).

**Infections:** Number of febrile neutropenia (FEN) attacks.

Genetic Analysis {#s2c}
----------------

Peripheral blood samples were collected from all patients when they were in remission. Genomic DNA isolation was performed using the standard salting-out method. N363S and BclI genotypes were determined by polymerase chain reaction (PCR)-restriction fragment length polymorphism. PCR was performed in total volumes of 20 µL containing 0.1 µg of genomic DNA, 10 pmol of each primer (forward: 5'-CCAGTAATGTAACACTGCCCC-3', reverse: 5'-TTCGACCAGGGGAAGTTCAGA-3' for N363S and forward: 5'-GAGAAATTCACCCCTACCAAC-3', reverse: 5'-AGAGCCCTATTCTTCAAACTG-3' for BclI), 0.2 mM of each dNTP, 10 mM Tris, 50 mM KCl, 1.5 mM MgCl2, and 1 U of Taq polymerase. PCR conditions were as follows: initial denaturation at 95 °C for 4 min and then 30 cycles of 95 °C for 1 min, 56 °C for 1 min, and 72 °C for 1 min, followed by a final extension at 72 °C for 7 min. Restriction digestion was performed in total volumes of 20 µL containing 10 µL of PCR product and 2 U of restriction enzyme (Tsp5091 for N363S and BclI for BclI). Reaction mixtures were incubated overnight at 65 °C for Tsp5091 and at 55 °C for BclI. Genotypes were determined by 2% agarose gel electrophoresis of restriction digests. In the absence of the N363S polymorphism, a 357-bp PCR product gave restriction fragments of 135, 73, 70, 60, and 19 bp, whereas the polymorphic allele produced four fragments of 135, 92, 70, and 60 bp. For the BclI polymorphism, 418-bp PCR products gave two fragments of 263 and 151 bp, whereas the polymorphic allele remained uncut.

Statistical Analysis {#s2d}
--------------------

Data analysis was done using SPSS 11.5 for Windows. The Kolmogorov-Smirnov test was used to investigate whether the distribution of discrete numerical variables was near normal. Descriptive statistics for discrete numerical variables were shown as a median (minimum-maximum). The number of cases and the categorical variables were shown as frequency percentage (%).

For comparison of the groups, the Mann-Whitney U test was used when the number of independent groups was 2 and the Kruskal-Wallis test was used when the number was \>2.

We tested for Hardy-Weinberg equilibrium for allele and genotype frequencies and they were found to be in equilibrium in both the patient and control groups.

Categorical variables were investigated by Pearson chi-square or Fisher exact test. For the comparison of allele and genotype frequencies of the control and patient groups and for comparison of side effect frequencies between the genotypes we used the Pearson chi-square test and Fisher exact chi-square test. The Cochran Q test was used to investigate whether there was significant change in osteoporosis incidence during follow-up of patients. Values of p\<0.05 were considered statistically significant.

RESULTS {#s3}
=======

We did not find any statistically significant difference between the control and patient groups as to age (8.7 vs. 7.0 years, p=0.33) and sex (male and female: 47.8% vs. 63.3% and 52.2% vs. 36.7%, p=0.130, respectively) distribution. There was no N363S polymorphism in either the patient or the control group ([Table 1](#t1){ref-type="table"}).

The heterozygosity rates of the BclI polymorphism in the control and patient groups were 37% (n=17) and 46.9% (n=23) while the homozygosity rates were 4.3% (n=2) and 12.2% (n=6), respectively. C allele frequencies in the control and patient groups were 69.8% and 59.7% and G allele frequencies 30.2% and 40.3%, respectively. There was no statistically significant difference between the two groups as to allele and polymorphism frequency ([Table 1](#t1){ref-type="table"}).

Induction Phase {#s3a}
---------------

Because two patients had received the induction phase of ALL therapy at another center, we performed induction phase investigations on 47 patients. In [Table 2](#t2){ref-type="table"} the frequencies of adverse events seen during induction are listed. We performed hip MRI for 9 patients and only one of them had grade I avascular necrosis.

Dyspeptic symptoms were more frequent among patients with CG rather than CC genotype (36.4% vs. 5.3%, p=0.018) ([Table 3](#t3){ref-type="table"}). Depression symptoms were more frequent among polymorphism carriers (CG+GG genotypes) than non-carriers (39.3% vs. 10.5%, p=0.031) ([Table 3](#t3){ref-type="table"}). There was no significant difference between polymorphism carriers and non-carriers as to hyperglycemia, hypertriglyceridemia, Cushingoid changes, liver function test abnormality, arthralgia, myalgia, muscle weakness, sinus tachycardia, thrombosis, number of FEN attacks, osteopenia and osteoporosis, and hypertension frequency ([Table 2](#t2){ref-type="table"}).

Reinduction Phase {#s3b}
-----------------

Because five patients had been treated at another center, we analyzed the side effects of 44 patients during the reinduction phase. In [Table 2](#t2){ref-type="table"} frequencies of adverse events seen during induction are listed. Nine patients were investigated by hip MRI for avascular necrosis. Three patients had osteonecrosis and two of them underwent bilateral hip joint replacement operations. At the end of reinduction we investigated 34 patients based on BMD for osteoporosis. Eight (23.5%) patients had no osteopenia or osteoporosis, but the corrected (for age) Z-scores of 14/34 patients (41.2%) were between -1 and -2.5. Twelve of 34 patients (35.3%) developed osteoporosis and one of these cases was grade 3 (limiting self-care) according to CTCAE v.4.

Cushingoid changes (54.3% vs. 17.6%, p=0.043), depression symptoms (50.0% vs. 11.8%, p=0.011), and dyspepsia (36.4% vs. 0.0%, p=0.008) were more frequent among patients with the CG genotype than those with the CC genotype ([Table 4](#t4){ref-type="table"}). Cushingoid changes (48.1% vs. 17.6%, p=0.041), dyspepsia (29.6% vs. 0.0%, p=0.016), and depression symptoms (40.7% vs. 11.8%, p=0.040) were more frequent among polymorphism carriers (CG+GG genotypes) than non-carriers ([Table 4](#t4){ref-type="table"}). There was no significant difference between polymorphism carriers and non-carriers as to hyperglycemia, hypertriglyceridemia, liver function test abnormality, arthralgia, myalgia, muscle weakness, sinus tachycardia, and thrombosis frequency ([Table 4](#t4){ref-type="table"}).

In total, 22 patients were investigated regularly for BMD at the time of diagnosis, at the end of induction, and at reinduction. There was no significant change between BMD at diagnosis, at the end of induction, and at the end of reinduction ([Table 5](#t5){ref-type="table"}).

DISCUSSION {#s4}
==========

Some children with leukemia experience the side effects of steroids much more so than others, even in an exaggerated manner. GC receptor polymorphisms (N363S and BclI) may cause a genetic predilection to increased sensitivity to GCs, and their early recognition may help clinicians to modify the steroid doses in future trials. In this study, in which we searched for the presence of GR polymorphisms that yield high sensitivity to GCs, we found that carriers of the BclI polymorphism were more prone to side effects of GCs like Cushingoid changes, dyspepsia, and depression symptoms for the first time in the literature as far as we know.

We found that the N363S polymorphism was absent in our population, consistent with the results in Asian populations in which no N363S polymorphism was found \[[@ref28]\]. Likewise, it was recently reported in a Turkish population that the frequency of N363S G allele carriers was 0.5% \[[@ref29]\]. In contrast to our results, in Europe, the frequency of carrying at least one G allele of the N363S polymorphism was reported to range from 4% to 9% \[[@ref26],[@ref28]\], highlighting the ethnic factors in its carriage.

The C allele of the BclI polymorphism is the most frequent allele and this is considered to be the wild type \[[@ref7]\]. The frequencies of the C and G alleles of the BclI polymorphism are about 65% and 35%, respectively \[[@ref7]\]. We found similar results to those in the literature in the control and patient groups with regard to C and G allele frequency ([Table 1](#t1){ref-type="table"}).

Marino et al. \[[@ref24]\] reported the frequencies of GC side effects during induction and reinduction in children with ALL who were treated according to the Italian BFM ALL 2000 study protocol. During the induction phase they found the frequency of depression as 69.4%, Cushingoid changes as 50.0%, hypertriglyceridemia as 8.3%, hyperglycemia as 22.2%, and hypertension as 5.6%. During the reinduction phase, they found the frequency of depression as 58.3%, Cushingoid changes as 58.3%, hyperglycemia as 22.2%, gastritis as 11.1%, hypertension as 2.7%, and hypertriglyceridemia as 0%. We have encountered some adverse events less frequently (Cushingoid changes, depression symptoms) or more frequently (hypertriglyceridemia, hyperglycemia, and hypertension) than Marino et al. \[[@ref24]\]. The differences between our results and those of Marino et al. \[[@ref24]\] may be due to ethnic and genetic differences. Both N363S and BclI polymorphisms are known to make patients more prone to the side effects of the GCs \[[@ref28],[@ref29],[@ref30],[@ref31]\]. The effects of GR gene mutations and polymorphisms on treatment success and drug resistance were also recently investigated and controversial results were obtained \[[@ref3],[@ref20],[@ref21],[@ref26]\]. In our study we did not investigate the effect of the BclI polymorphism on treatment success. Alternatively, we focused on the side effects of GCs and their relation with GR gene polymorphisms.

In the literature there are few studies about the side effects of GCs and GR polymorphisms. In Marino et al.'s \[[@ref24]\] study no relationship was found between the polymorphisms (N363S and BclI) and appetite, weight gain, Cushingoid changes, depression, anxiety, emotional lability, neuromuscular weakness, myalgia, or severity of infections in pediatric ALL patients during the induction and reinduction periods. Eipel et al. \[[@ref26]\] found that the BclI polymorphism was not associated with hepatotoxicity, glucose metabolism abnormalities, central nervous system or behavioral abnormalities, or hypertension. We found no relation between Cushingoid changes and the BclI polymorphism during the induction phase, but a more frequent Cushingoid appearance was seen in patients with CG+GG than in patients with the CC genotype during the reinduction phase ([Table 3](#t2){ref-type="table"}), in contrast to the results of Marino et al. \[[@ref24]\]. In their study Eipel et al. \[[@ref26]\] did not analyze Cushingoid appearance as a side effect. Other studies \[[@ref32],[@ref33]\] found higher levels of subcutaneous fat tissue in BclI polymorphism carriers than in non-carriers. Since Cushingoid changes are related to changes in the distribution of subcutaneous fat tissue, we think that our findings support these findings of previous studies \[[@ref32],[@ref33]\]. During the reinduction period we used high-dose dexamethasone, which is more potent than prednisolone \[[@ref23]\]. The discrepancy in the relationship between BclI polymorphism and Cushingoid appearance during the induction period while the opposite was observed during the reinduction phase may be due to the potency of dexamethasone.

We found that dyspepsia was more frequent in BclI polymorphism carriers than non-carriers during both phases ([Tables 3](#t2){ref-type="table"} and [4](#t3){ref-type="table"}). We could not find any information about the relationship between GR polymorphisms and dyspepsia or gastrointestinal disorders in the English literature. Therefore, our study seems to be the first study in the literature to report on this aspect, as well.

In our study, depression symptoms were more frequent in BclI polymorphism carriers during both phases ([Tables 3](#t2){ref-type="table"} and [4](#t3){ref-type="table"}). GCs are known to be related to adverse psychiatric side effects during pediatric ALL treatment \[33,34\]. Felder-Puig et al. \[[@ref23]\] and Eipel et al. \[[@ref26]\] found no relation between the BclI polymorphism and adverse psychiatric side effects in pediatric ALL patients. On the other hand, there are reports showing that the BclI polymorphism was more frequent in patients with major depression \[[@ref11],[@ref12]\]. Therefore, our results are consistent with those in the literature \[[@ref11],[@ref12]\].

Osteopenia and osteoporosis were more frequent in the CG and GG than in the CC genotype during the two phases, although the difference was not significant ([Tables 3](#t2){ref-type="table"} and [4](#t3){ref-type="table"}). Similarly, te Winkel et al. \[25\] reported no relationship between the BclI polymorphism and BMD in 69 pediatric ALL patients.

In conclusion, in our sample, the adequacy of which was confirmed by power analysis, we found that the N363S polymorphism was absent and the BclI polymorphism prevailed, and patients who were carriers of the BclI polymorphism were more prone to side effects of GCs like Cushingoid changes, dyspepsia, and depression symptoms. As far as we know, our study is the first to determine any relation between the BclI polymorphism and symptoms of depression and dyspepsia as side effects of GCs in childhood. The absence of the N363S polymorphism in our study sample in contrast with reports from other countries also highlights the variabilities of side effects of GCs in patients from different ethnic and geographic regions.

In our study, a larger number of patients with definite side effects (including those with sinus tachycardia and osteopenia/osteoporosis) and those consuming standard types of steroids could have provided further information about the relation between side effects and the BclI polymorphism during ALL treatment, which was the main limitation of our study. However, despite these limitations, this pilot study draws attention to the role of the BclI polymorphism on the development of particularly the aforementioned side effects during ALL treatment in Turkey and emphasizes that its role should be validated in further ethnic, regional, and global studies while designing individual treatment modalities.
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###### Distribution of N363S and BclI polymorphisms in control and patient groups.
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###### Frequencies of adverse events seen during the induction and reinduction phases.
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###### Side effect distributions of patient group during induction phase according to genotypes of BclI polymorphisms.
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###### Side effect distributions of patient group during reinduction phase according to genotypes of BclI polymorphism
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###### Distribution of bone mineral densitometry results of the patient group.
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